Coenzyme Q10 and spinocerebellar ataxias
العنوان: | Coenzyme Q10 and spinocerebellar ataxias |
---|---|
المؤلفون: | Lo, RY, Figueroa, KP, Pulst, SM, Lin, CY, Perlman, S, Wilmot, G, Gomez, C, Schmahmann, J, Paulson, H, Shakkottai, VG, Ying, S, Zesiewicz, T, Bushara, K, Geschwind, M, Xia, G, Subramony, SH, Ashizawa, T, Kuo, SH |
المصدر: | Movement disorders : official journal of the Movement Disorder Society, vol 30, iss 2 Lo, RY; Figueroa, KP; Pulst, SM; Lin, CY; Perlman, S; Wilmot, G; et al.(2015). Coenzyme Q10 and spinocerebellar ataxias. Movement Disorders, 30(2), 214-220. doi: 10.1002/mds.26088. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/3bb3x728 |
بيانات النشر: | eScholarship, University of California, 2015. |
سنة النشر: | 2015 |
مصطلحات موضوعية: | Adult, Male, Neurology & Neurosurgery, Ubiquinone, Clinical Sciences, neurodegeneration, Human Movement and Sports Sciences, Middle Aged, Severity of Illness Index, statins, Huntington Disease, Treatment Outcome, Surveys and Questionnaires, coenzyme Q10, Disease Progression, Humans, Spinocerebellar Ataxias, Female, Cognitive Sciences, Age of Onset, Aged |
الوصف: | © 2014 International Parkinson and Movement Disorder Society. The aim of this study was to investigate the association between drug exposure and disease severity in SCA types 1, 2, 3 and 6. The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) enrolled 319 participants with SCA1, 2, 3, and 6 from 12 medical centers in the United States and repeatedly measured clinical severity by the Scale for Assessment and Rating of Ataxia (SARA), the Unified Huntington's Disease Rating Scale part IV (UHDRS-IV), and the 9-item Patient Health Questionnaire during July 2009 to May 2012. We employed generalized estimating equations in regression models to study the longitudinal effects of coenzyme Q10 (CoQ10), statin, and vitamin E on clinical severity of ataxia after adjusting for age, sex, and pathological CAG repeat number. Cross-sectionally, exposure to CoQ10 was associated with lower SARA and higher UHDRS-IV scores in SCA1 and 3. No association was found between statins, vitamin E, and clinical outcome. Longitudinally, CoQ10, statins, and vitamin E did not change the rates of clinical deterioration indexed by SARA and UHDRS-IV scores within 2 years. CoQ10 is associated with better clinical outcome in SCA1 and 3. These drug exposures did not appear to influence clinical progression within 2 years. Further studies are warranted to confirm the association. |
وصف الملف: | application/pdf |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::9234147bba3810984f00d67ab276e710 https://escholarship.org/uc/item/3bb3x728 |
حقوق: | OPEN |
رقم الأكسشن: | edsair.dedup.wf.001..9234147bba3810984f00d67ab276e710 |
قاعدة البيانات: | OpenAIRE |
الوصف غير متاح. |